Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierBoRdeaux Institute in onCology [Inserm U1312 - BRIC]
dc.contributor.authorSALA, Margaux
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorGONZALES, Delphine
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorLESTE-LASSERRE, Thierry
hal.structure.identifierTBM-Core [Bordeaux] [UMS3427 - INSERM US005]
dc.contributor.authorDUGOT-SENANT, Nathalie
dc.contributor.authorPARADIS, Valerie
hal.structure.identifierTBM-Core [Bordeaux] [UMS3427 - INSERM US005]
hal.structure.identifierBoRdeaux Institute in onCology [Inserm U1312 - BRIC]
dc.contributor.authorDI TOMMASO, Sylvaine
hal.structure.identifierCentre Génomique Fonctionnelle Bordeaux [Bordeaux] [CGFB]
hal.structure.identifierPlateforme Protéome [Bordeaux]
dc.contributor.authorDUPUY, Jean-William
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorPITARD, Vincent
hal.structure.identifierTBM-Core [Bordeaux] [UMS3427 - INSERM US005]
hal.structure.identifierBoRdeaux Institute in onCology [Inserm U1312 - BRIC]
dc.contributor.authorDOURTHE, Cyril
dc.contributor.authorSCIARRA, Amadeo
dc.contributor.authorSEMPOUX, Christine
dc.contributor.authorFERRELL, Linda D.
dc.contributor.authorCLOUSTON, Andrew D.
dc.contributor.authorMILLER, Gregory
dc.contributor.authorYEH, Mathew M.
dc.contributor.authorTHUNG, Swan
dc.contributor.authorGOUW, Annette S.H.
dc.contributor.authorQUAGLIA, Alberto
dc.contributor.authorHAN, Jing
dc.contributor.authorHUAN, Ji
dc.contributor.authorFAN, Cathy
dc.contributor.authorCRAWFORD, James
dc.contributor.authorNAKANUMA, Yasuni
dc.contributor.authorHARADA, Kenichi
hal.structure.identifierBoRdeaux Institute in onCology [Inserm U1312 - BRIC]
dc.contributor.authorLE BAIL, Brigitte
dc.contributor.authorCASTAIN, Claire
dc.contributor.authorFRULIO, Nora
hal.structure.identifierImagerie moléculaire et thérapies innovantes en oncologie [IMOTION]
dc.contributor.authorTRILLAUD, Herve
dc.contributor.authorPOSSENTI, Laurent
dc.contributor.authorCHICHE, Laurence
dc.contributor.authorLAURENT, Christophe
hal.structure.identifierBoRdeaux Institute in onCology [Inserm U1312 - BRIC]
dc.contributor.authorBIOULAC-SAGE, Paulette
hal.structure.identifierTBM-Core [Bordeaux] [UMS3427 - INSERM US005]
hal.structure.identifierBoRdeaux Institute in onCology [Inserm U1312 - BRIC]
dc.contributor.authorRAYMOND, Anne-Aurelie
hal.structure.identifierTBM-Core [Bordeaux] [UMS3427 - INSERM US005]
hal.structure.identifierBoRdeaux Institute in onCology [Inserm U1312 - BRIC]
dc.contributor.authorSALTEL, Frederic
dc.date.accessioned2023-05-23T14:56:02Z
dc.date.available2023-05-23T14:56:02Z
dc.date.issued2020-04-11
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/182279
dc.description.abstractEnUntil recently, 10% of hepatocellular adenomas (HCAs) remained unclassified (UHCA). Among the UHCAs, the sonic hedgehog HCA (shHCA) was defined by focal deletions that fuse the promoter of Inhibin beta E chain with GLI1. Prostaglandin D2 synthase was proposed as immunomarker. In parallel, our previous work using proteomic analysis showed that most UHCAs constitute a homogeneous subtype associated with overexpression of argininosuccinate synthase (ASS1). To clarify the use of ASS1 in the HCA classification and avoid misinterpretations of the immunohistochemical staining, the aims of this work were to study (1) the link between shHCA and ASS1 overexpression and (2) the clinical relevance of ASS1 overexpression for diagnosis. Molecular, proteomic, and immunohistochemical analyses were performed in UHCA cases of the Bordeaux series. The clinico-pathological features, including ASS1 immunohistochemical labeling, were analyzed on a large international series of 67 cases. ASS1 overexpression and the shHCA subgroup were superimposed in 15 cases studied by molecular analysis, establishing ASS1 overexpression as a hallmark of shHCA. Moreover, the ASS1 immunomarker was better than prostaglandin D2 synthase and only found positive in 7 of 22 shHCAs. Of the 67 UHCA cases, 58 (85.3%) overexpressed ASS1, four cases were ASS1 negative, and in five cases ASS1 was noncontributory. Proteomic analysis performed in the case of doubtful interpretation of ASS1 overexpression, especially on biopsies, can be a support to interpret such cases. ASS1 overexpression is a specific hallmark of shHCA known to be at high risk of bleeding. Therefore, ASS1 is an additional tool for HCA classification and clinical diagnosis. © 2020 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subject.enArgininosuccinate Synthase
dc.subject.enGlutamate Ammonia Ligase
dc.subject.enHemagglutinin
dc.subject.enProstaglandin D2
dc.subject.enSerum Amyloid A
dc.subject.enSmall Interfering Rna
dc.subject.enSonic Hedgehog Protein
dc.subject.enVimentin
dc.subject.enArticle
dc.subject.enAss1 Gene
dc.subject.enBody Mass
dc.subject.enClinical Practice
dc.subject.enDisease Association
dc.subject.enGene
dc.subject.enGene Overexpression
dc.subject.enGenetic Transfection
dc.subject.enGenotyping Technique
dc.subject.enHedgehog Signaling
dc.subject.enHuman
dc.subject.enHuman Tissue
dc.subject.enImmunohistochemistry
dc.subject.enLiquid Chromatography-Mass Spectrometry
dc.subject.enLiver Adenoma
dc.subject.enLiver Fibrosis
dc.subject.enLiver Injury
dc.subject.enMetabolic Syndrome X
dc.subject.enMicroarray Analysis
dc.subject.enObesity
dc.subject.enPhenotype
dc.subject.enPriority Journal
dc.subject.enPromoter Region
dc.subject.enProtein Expression
dc.subject.enProteomics
dc.subject.enReal Time Reverse Transcription Polymerase Chain Reaction
dc.subject.enRisk Factor
dc.subject.enRna Extraction
dc.subject.enRna Isolation
dc.subject.enTumor Recurrence
dc.subject.enUpregulation
dc.subject.enWestern Blotting
dc.title.enASS1 Overexpression: A Hallmark of Sonic Hedgehog Hepatocellular Adenomas; Recommendations for Clinical Practice
dc.title.alternativeHepatol Communen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1002/hep4.1514en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.identifier.pubmed32490318en_US
bordeaux.journalHepatology Communicationsen_US
bordeaux.page809-824en_US
bordeaux.volume4en_US
bordeaux.hal.laboratoriesNeurocentre Magendie - U1215en_US
bordeaux.issue6en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamPlateforme Transcriptomeen_US
bordeaux.teamGénotypageen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04104081
hal.version1
hal.date.transferred2023-05-23T14:56:19Z
hal.exporttrue
dc.rights.ccCC BY-NC-NDen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Hepatology%20Communications&rft.date=2020-04-11&rft.volume=4&rft.issue=6&rft.spage=809-824&rft.epage=809-824&rft.au=SALA,%20Margaux&GONZALES,%20Delphine&LESTE-LASSERRE,%20Thierry&DUGOT-SENANT,%20Nathalie&PARADIS,%20Valerie&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée